Physician profile
Sameed K Lodhi
NPI 1356827182
$1,979.59
in general payments reported to CMS, 2019-2025
19 companies · $850 in 2025
The $850 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $220 · 2024: $909 · 2025: $850.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,976 · Education: $3.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,976.14 |
| Education | $3.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $251.32 | 2024-2025 | Xphozah 30 Mg, Ibsrela |
| Nxstage Medical, INC. | $220.76 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $167.29 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $155.91 | 2024-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $151.64 | 2023-2025 | Farxiga |
| Otsuka America Pharmaceutical, INC. | $146.95 | 2023-2025 | Jynarque |
| Travere Therapeutics, INC. | $141.03 | 2024-2025 | |
| Fresenius USA Marketing, INC. | $136.66 | 2024-2025 | Liberty Select Cycler, Nxstage System One, Velphoro |
| Cardiovascular Systems INC. | $135.90 | 2023 | Diamondback Coronary |
| Calliditas Therapeutics US INC. | $112.84 | 2024-2025 | Tarpeyo |
| Novartis Pharmaceuticals Corporation | $85.58 | 2024-2025 | |
| Amgen INC. | $79.15 | 2024-2025 | Tavneos, Krystexxa |
| Glaxosmithkline, LLC. | $46.44 | 2025 | Benlysta |
| Vifor Pharma, INC. | $37.36 | 2023-2024 | Veltassa, Korsuva |
| Apellis Pharmaceuticals, INC. | $31.84 | 2025 | Empaveli |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $21.75 | 2025 | Jardiance |
| Mallinckrodt Hospital Products INC. | $21.25 | 2024 | Terlivaz |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $18.89 | 2025 | |
| Opko Pharmaceuticals, LLC | $17.03 | 2025 | Rayaldee |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sameed Lodhi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.